| Project/Area Number |
17591455
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
NITTA Yoshio Tohoku University, Tohoku University Hospital, Assistant Professor (80375005)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TABAYASHI Koichi Graduate School of Medicine, 大学院・医学系研究科, Professor (90142942)
SAI Sadahiro Tohoku University Hospital, 病院, Lecturer (60312576)
SAIKI Yoshikatsu Tohoku University Hospital, 病院, Lecturer (50372298)
ODA Katsuhiko Graduate School of Medicine, 大学院・医学系研究科, Assistant Professor (60323002)
AKASAKA Junetsu Tohoku University Hospital, 病院, Assistant Professor (80343044)
|
|---|
| Project Period (FY) |
2005 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥3,690,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥90,000)
Fiscal Year 2007: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2006: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2005: ¥2,300,000 (Direct Cost: ¥2,300,000)
|
|---|
| Keywords | slow-released / vessel growth factor / inhaled drug / pulmonary artery bed / Fontan / 薬剤徐放 / ゼラチンハイドロゲル / 血管新生 / 肺血管床 / 経気管支投与 / 徐放 / フォンタン手術 / 先天性心疾患 |
|---|
| Research Abstract |
[Background] The Fontan type right heart bypass surgery is a useful functional repair method for single ventricle type congenital heart diseases. However, the key of successful surgery depends on the level of development of pulmonary artery bed. Patients have to wait several months until the pulmonary artery bed develop enough, and not all of them survive this waiting period with unstable hemodynamics.
[Purpose] To establish the inhaled slow-released vessel growth factor delivery system using gelatin hydrogel microspheres.[Methods & Results] Gelatin hydrogel microspheres impregnated with basic fibroblast growth factor (bFGF) were implanted to the rat subcutaneously with or without systemic granulocyte-colony stimulating factor (G-CSF). Histological examination demonstrated significantly higher number of capillaries in the treatment groups compared with the sham control group. Rats were intubated and gelatin hydrogel microsphere solution was infused under general anesthesia. The distribution of inhaled gelatin hydrogel microspheres was evaluated and was not uniform. [Discussion] Slow-released bFGF with or without systemic G-CSF induced angiogenesis . subcutaneously. Though the distribution of inhaled gelatin hydrogel microspheres was uneven in the lung, this method is allowed to perform again and again. Plural administration from different drug release points may correct the uneven distribution. On the other hand, our preliminary data showed that uniform reporter gene expression in the lung was observed after the vector solution infusion via pulmonary artery. However, the gene therapy method required to stop the pulmonary blood flow transiently, and may not be safe for the heart disease patients. Inhaled slow-released drug delivery method is relatively safe and easy, and could be a promising tool for the single ventricle type congenital heart disease patients.
|
